giant cell


Also found in: Thesaurus, Medical, Legal, Financial, Encyclopedia, Wikipedia.

giant cell

n
(Biology) histology an exceptionally large cell, often possessing several nuclei, such as an osteoclast
References in periodicals archive ?
The cost watchdog's ruling means it is unlikely that patients with giant cell arteritis will have access to the treatment any time soon.
Giant cell arteritis (GCA) is the most common vasculitis of the elderly, primarily affecting individuals over 50 years of age.
Differentials include fibrous dysplasia, cherubism, giant cell tumor.
Background: Intralesional excision with curettage is the standard method of giant cell tumor (GCT) treatment, but the ideal filling material after curettage remains controversial.
Giant cell arteritis (GCA) is an inflammatory lesion of the large- and medium-sized arteries, which usually involves the cranial arteries of older women.
THE FOOD AND DRUG Administration has approved subcutaneous tocilizumab (Actemra) for the treatment of giant cell arteritis.
These rare breast lesions are fibromatosis, idiopathic granulomatous mastitis, tubular adenoma, diabetic mastopathy, invasive micropapillary carcinoma, osteoclastic giant cell breast carcinoma, malignant phyllodes tumor, carcinoma arising in fibroadenoma, metastasis, and metaplastic carcinoma.
com/article/S0049-0172(00)67567-4/abstract) study from researchers in New Jersey found that giant cell myocarditis (GCM) is the most fatal autoimmune disease.
24 One patient with jaw mass had a giant cell granuloma, which is rarely seen as a sole manifestation of PHPT.
There are two forms of ABC- Primary (Occurring de novo) and secondary which complicates other benign and malignant conditions like-Fibrous Dysphasia, Osteoblastoma, Osteosarcoma, Chondroblastoma, Giant Cell tumour, chondromyxoid fibroma, non-ossifying fibroma.
There are also about 11,000 people with the more serious condition giant cell arteritis, a condition in which medium and large arteries, usually in the head and neck, become inflamed.
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that it will discontinue additional enrollment of the phase 3 ENLIVEN study of the investigational oral CSF-1R inhibitor pexidartinib (PLX3397) in tenosynovial giant cell tumor; however, the study will proceed with currently enrolled patients under a revised protocol.